[1] 汤钊猷.肝癌治疗研究的现状与展望[J].肿瘤,1995,15(3): 249-251.[2] Simonetti RG, Cammà C, Fiorello F, et al. Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci. 1991;36(7):962-972. [3] Okuda K, Peters RL, Simson IW. Gross anatomic features of hepatocellular carcinoma from three disparate geographic areas. Proposal of new classification. Cancer. 1984;54(10): 2165-2173. [4] Lübbe AS, Alexiou C, Bergemann C. Clinical applications of magnetic drug targeting. J Surg Res. 2001;95(2):200-206. [5] 张武,肖健存.原发性肝癌介入治疗的现状与展望[J].中国微创外科杂志,2001,1(2):111-113.[6] Gray BN. Colorectal cancer: the natural history of disseminated disease - a review. Aust N Z J Surg. 1980;50(6):643-646. [7] Kreuter J. Nanoparticles and microparticles for drug and vaccine delivery. J Anat. 1996;189 ( Pt 3):503-505. [8] Torchilin VP. Drug targeting. Eur J Pharm Sci. 2000;11 Suppl 2:S81-91. [9] Tomlinson E. Site-specific drug carriers. Eng Med. 1986;15(4): 197-202. [10] Gavrilov K, Saltzman WM. Therapeutic siRNA: principles, challenges, and strategies. Yale J Biol Med. 2012;85(2): 187-200. [11] Berger G, Reszka R, Pohlen U, et al. Liposome encapsulation of cystostatic drugs and starch microspheres improve tumor targeting in locoregional therapy. An animal experiment study of CC 531 liver tumor. Langenbecks Arch Chir Suppl Kongressbd. 1998;115(Suppl I):693-697. [12] Kokudo N, Vera DR, Tada K, et al. Predictors of successful hepatic resection: prognostic usefulness of hepatic asialoglycoprotein receptor analysis. World J Surg. 2002; 26(11):1342-1347. [13] Hashida M, Akamatsu K, Nishikawa M, et al. Design of polymeric prodrugs of prostaglandin E(1) having galactose residue for hepatocyte targeting. J Control Release. 1999; 62(1-2):253-262. [14] 陆才德.肝脏肿瘤血供[J].国外医学:肿瘤学分册,1991,18(1): 19-22.[15] 中国知网.中国学术期刊总库[DB/OL].2012-08-16. https://www.cnki.net.[16] 冯晶晶,雷炜,姚如永.靶向survivin的siRNA并氟尿嘧啶转染对HepG2增殖影响[J].齐鲁医学杂志,2012,27(2):95-97.[17] 卢昕,郑启昌.靶向survivin的siRNA诱导肝癌细胞化疗敏感性的研究[J].中国普通外科杂志,2010,19(8):875-880.[18] 王骋.表阿霉素聚氰基丙烯酸正丁酯纳米粒治疗移植性肝癌的实验研究[D].湖南:中南大学,2009:1-67.[19] 彭健,刘鑫,王荣兵,等.5-氟尿嘧啶磁性纳米脂质体在大鼠肝癌模型体内的靶向分布[J].中国现代医学杂志,2007,17(24): 2952-2956.[20] 李育超,周克元,蔡春,等.肝靶向药物Gal-HSA-5-FU对Bel-7402肝癌细胞增殖和细胞周期的影响[J].广东医学院学报,2007, 25(5):515-518.[21] 牛坚,李向农,黄健,等.siRNA封闭IGF1R增加人肝癌细胞对丝裂霉素敏感性的研究[J].肿瘤,2007,27(11):870-873.[22] 周嘉嘉,陈汝福,唐启彬,等.载5-氟尿嘧啶两亲多糖纳米粒的制备及其对肝癌细胞HepG2的杀伤作用[J].癌症,2006,25(12): 1459-1463.[23] 吕琳.表阿霉素聚氰基丙烯酸正丁酯磁性纳米粒的研制及用于肝癌靶向治疗的实验研究[D].湖南:中南大学,2006:1-79.[24] 任非,陈建海,陈志良,等.MMC-聚氰基丙烯酸正丁酯磁性纳米球对BEL-7402人肝癌细胞裸小鼠移植瘤的作用[J].第四军医大学学报,2005,26(16):1510-1512.[25] 杨秉辉.原发性肝癌的临床诊断与分期标准[J].中华肝脏病杂志, 2001,9(6):324.[26] 李琴,王宝恩,贾继东.肝功能分级的演变及特点:从Child到MELD[J].中华肝脏病杂志,2004,12(5):319-320.[27] 张贺龙.实体瘤疗效评价标准及演变[J].现代肿瘤医学,2010, 18(5):839-841.[28] 林志东,文宠佩,符孔,等.肝癌肝外血管多层螺旋CT三维重建的临床应用[J].介入放射学杂志,2010,l9(8):607-609.[29] 杨伟洪,刘鹏程.MSCTA对肝癌寄生血管的评价及其对TACE的价值[J]. 罕少疾病杂志,2007,14(5):55-58.[30] 易城辉,丁来贵,袁福建,等.TACE术在肝癌治疗中的作用及其疗效分析[J].中国实用医药,2009,4(11):96-97.[31] 张小华,罗伟炎,李舒刚,等.经导管动脉内灌注化疗栓塞术治疗中晚期肝癌13例[J].赣南医学院学报,2001,21(4):391-393.[32] 杨治国.肝动脉化疗栓塞在晚期肝癌中的应用[J].中外医疗,2011, 30(32):37-38.[33] 范文哲,李家平,杨建勇,等.无法手术切除的肝细胞癌TACE与RFA治疗的Meta分析[J].中华普通外科学文献(电子版),2011, 5(1):51-54.[34] 狄纪君,郭卫东,张惠洁,等.TACE联合热疗治疗原发性肝癌的临床观察[J].临床肿瘤学杂志,2012,17(1):42-46.[35] 毕品端,曹光琼,吴韬,等.TACE联合体部伽玛刀治疗原发性肝癌生存因素的探讨[J].山东医药,2010,50(1):98-99.[36] 陈云萍,张江灵,罗丹凤.伽玛刀联合介入治疗原发性肝癌与单纯介入治疗原发性肝癌临床疗效分析[J].临床荟萃,2011,26(3): 220-222.[37] 蔡茂怀,夏月琴,刘菊林.肝动脉加腹腔双重灌注治疗晚期肝癌的初步研究[J].中国现代医学杂志,2000,10(1):24-25.[38] 郭俊渊.现代腹部影像诊断学[M].北京:科学出版社,2001: 519-561.[39] Higashihara H, Okazaki M. Transcatheter arterial chemoembolization of hepatocellular carcinoma: a Japanese experience. Hepatogastroenterology. 2002;49(43):72-78. [40] Kim HC, Chung JW, Lee W, et al. Recognizing extrahepatic collateral vessels that supply hepatocellular carcinoma to avoid complications of transcatheter arterial chemoembolization. Radiographics. 2005;25 Suppl 1:S25-39. |